Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

global health inequality

- PMLiVE

Sandoz launches first and only multiple sclerosis biosimilar in US

The treatment is FDA-approved to treat MS and Crohn’s disease

- PMLiVE

Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities

Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity

EU flag

EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

- PMLiVE

FDA grants interchangeable designation to Celltrion’s Humira biosimilar Yuflyma

The drug is approved for inflammatory conditions such as Crohn's disease and plaque psoriasis

EU flag

EC approves Biocon’s Stelara biosimilar Yesintek for inflammatory diseases

The drug has been approved to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease

EU flag

EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases

The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications

- PMLiVE

Sandoz receives FDA approval for first denosumab biosimilars Wyost and Jubbonti

The biosimilars have been authorised for all indications covered by Amgen's reference medicines

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

- PMLiVE

Sandoz biosimilar receives EC approval to treat MS

Tyruko is the first and only biosimilar treatment for relapsing-remitting MS in Europe

- PMLiVE

Sandoz’s Tyruko approved by FDA as first biosimilar for relapsing multiple sclerosis

The disease-modifying therapy is approved to treat all indications covered by Tysabri

- PMLiVE

Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US

Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links